RIGL — Rigel Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $882.62m
- $826.53m
- $294.28m
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)
U.S. STOCKS ON THE MOVE-Tyler Technologies, Autodesk, Illumina
U.S. STOCKS ON THE MOVE-BuzzFeed, GameStop, Under Armour
Rigel rises on licensing deal for Pfizer-Arvinas breast cancer drug
U.S. STOCKS ON THE MOVE-Under Armour, C3 AI, Rigel Pharma
Rigel rises on licensing deal for Pfizer-Arvinas breast cancer drug
Rigel strikes licensing deal for Pfizer and Arvinas' breast cancer drug
Brief: Rigel Enters Exclusive Global Licensing Agreement For Veppanu
Rigel Pharmaceuticals Q1 revenue misses estimates; sees profitable FY
Licensing Agreement For "Olutasidenib" With Orient Europharma In Taiwan
Brief: Rigel Pharmaceuticals Inc On April 16, Received Written Notice From Eli Lilly
Brief: Rigel Announces Publication Of Final Arrow Clinical Trial Data On Gavreto® (Pralsetinib)
Rigel Pharmaceuticals prelim Q4 revenue beats estimates
Brief: Rigel Pharmaceuticals, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Comerica, Heico, Walmart
U.S. RESEARCH ROUNDUP-Alignment Healthcare, BJ's Wholesale Club Holdings, Hyatt Hotels